CERO Therapeutics Holdings, Inc. announced on March 6, 2025, the execution of an agreement with CellCarta, a contract research organization (CRO). This partnership is aimed at managing translational assays for the company’s upcoming Phase 1 clinical trial of CER-1236 for Acute Myeloid Leukemia (AML).
CellCarta will be responsible for critical data elements, including pharmacokinetics, cytokine secretion, and target detection, which are essential readouts beyond safety data in a Phase 1 trial. The CRO will also provide support to clinical trial sites for sample kitting, shipment, and overall logistics, ensuring the integrity of clinical samples.
This agreement represents important progress as CERO Therapeutics prepares to enroll patients in the trial. CEO Chris Ehrlich stated that each new milestone brings the company closer to patient enrollment and that diligent work is ongoing to ensure all aspects of the trial are ready for execution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.